High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

Description

The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

Conditions

Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

Implementation of High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Infliximab or Vedolizumab

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

Condition
Inflammatory Bowel Disease
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Existing diagnosis of IBD, including Crohn disease, ulcerative colitis, and indeterminate colitis
  • * Receiving treatment with Infliximab or Vedolizumab every 4-8 weeks
  • * Age 5-25 years old, at study entry
  • * Measured serum level of 25-OHD of less than 40 ng/mL in the last 4-8 weeks and no changes in vitamin D supplementation in the interim. Of note, 25-OHD levels are evaluated routinely as part of standard clinical care for IBD
  • * History of any underlying kidney disease
  • * History of preexisting liver disease
  • * History of granulomatous disease
  • * Inability to take oral vitamin D3 as a pill
  • * History of hypercalcemia or hypercalciuria
  • * Currently, or within the past 3 months, taking an anti-epileptic medication or Lasix

Ages Eligible for Study

5 Years to 25 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Boston Children's Hospital,

Rebecca Gordon, MD, PRINCIPAL_INVESTIGATOR, Boston Children's Hospital

Study Record Dates

2024-09